Active — Not RecruitingNot Applicable

Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomeningeal Metastasis

United States20 participantsStarted 2025-05-14

Plain-language summary

The purpose of this study is to confirm the safety and efficacy of linac based Volumetric Modulated Arc Therapy (VMAT) for craniospinal irradiation (CSI) in solid tumor cancer patients with leptomeningeal metastasis. The primary aim is to determine if linac based VMAT CSI for leptomeningeal metastasis improves central nervous system (CNS) progression free survival (PFS) compared to the historical standard control CNS PFS in patients treated with Involved Field Radiation Therapy (IFRT).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Solid tumor cancer primary with leptomeningeal metastases established radiographically and/or by CSF cytology
✓. Candidate for radiation therapy for the treatment of leptomeningeal metastases
✓. If patient had prior radiation, a treatment plan can be generated that will not exceed normal tissue tolerances
✓. Patient must have reasonable systemic treatment options, as confirmed by their medical oncologist
✓. Age ≥ 18 years old
✓. Able to provide informed consent
✓. Karnofsky Performance Scale (KPS) ≥ 60
✓. Adequate hematologic baseline

Exclusion criteria

✕. Patient has multiple severe neurologic deficits per physician assessment
✕. Patient has diffuse systemic disease without reasonable systemic therapy options
✕. Patient is unable to undergo MRI brain and spine with gadolinium contrast
✕. Prior radiation that would preclude development of a treatment plan that respects normal tissue constraints
✕. Pregnant or lactating women
✕

What they're measuring

Time to central nervous system (CNS) progression free survival

Timeframe: From baseline up to 1 year from end of treatment

Trial details

NCT IDNCT06984523

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-05-12

View on ClinicalTrials.gov More Leptomeningeal Metastasis trials